
    
      This is a Phase 1, single center, single-ascending dose, sequential, randomized, and
      crossover study.

      Following a Screening period of up to 21 days, eligible subjects will be randomized different
      dosing sequences, with approximately 4 subjects allocated to each dosing sequence. The total
      in-clinic duration for each subject will be 24 days (including the admission day prior to the
      first dosing period).
    
  